A Southeast Asia Consensus on the Definition and Management of Treatment-Resistant Depression

References

• GBD 2017 Disease and Injury Incidence and Prevalence Collabolators. Global, regional and national incidence, prevalence, and years lived with disability for 354 disease and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1789–1858. doi:10.1016/S0140-6736(18)32279-7
   Web of Science ®Google Scholar
• Bennabi D, Charpeaud T, Yrondi A, et al. Clinical guidelines for the management of treatment-resistant depression: french recommendations from experts, the French Association for biological psychiatry and neuropsychopharmacology and the foundation fondaMental. BMC Psychiatry. 2019;19(1):262. doi:10.1186/s12888-019-2237-x
   Web of Science ®Google Scholar
• Dold M, Kasper S. Evidence-based pharmacotherapy of treatment-resistant unipolar depression. Int J Psychiatry Clin Pract. 2017;21(1):13–23. doi:10.1080/13651501.2016.1248852
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. doi:10.1176/ajp.2006.163.11.1905
   PubMed Web of Science ®Google Scholar
• Bergfeld IO, Mantione M, Figee M, Schuurman PR, Lok A, Denys D. Treatment-resistant depression and suicidality. J Affect Disord. 2018;235:362–367. doi:10.1016/j.jad.2018.04.016
   PubMed Web of Science ®Google Scholar
• Johnston KM, Powell LC, Anderson IM, Szabo S, Cline S. The burden of treatment-resistant depression: a systematic review of the economic and quality of life literature. J Affect Disord. 2019;242:195–210. doi:10.1016/j.jad.2018.06.045
   PubMed Web of Science ®Google Scholar
• Klug J, Yu F, Chang C, et al. Estimating the economic burden of treatment resistant depression in Taiwan using the NHIRD. Value Health. 2016;19:A840–1.
   Web of Science ®Google Scholar
• Souery D, Oswald P, Massat I, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68(7):1062–1070. doi:10.4088/jcp.v68n0713
   PubMed Web of Science ®Google Scholar
• Kubitz N, Vossen C, Papadimitropoulou K, Karabis A. The prevalence and disease burden of treatment-resistant depression – a systematic review of the literature. Value Health. 2014;17:A455–6.
   PubMed Web of Science ®Google Scholar
• Mahlich J, Tsukazawa S, Wiegand F. Estimating prevalence and healthcare utilization for treatment-resistant depression in Japan: a retrospective claims database study. Drugs Real World Outcomes. 2018;5(1):35–43. doi:10.1007/s40801-017-0126-5
   PubMedGoogle Scholar
• Fife D, Feng Y, Wang M, et al. Epidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan. Psychiatry Res. 2017;252:277–283. doi:10.1016/j.psychres.2017.03.006
   PubMed Web of Science ®Google Scholar
• Ng CH, Kato T, Han C, et al. Definition of treatment-resistant depression – Asia Pacific perspectives. J Affect Disord. 2019;245:626–636. doi:10.1016/j.jad.2018.11.038
   PubMed Web of Science ®Google Scholar
• Fife D, Reps J, Cepeda MS, Stang P, Blacketer M, Singh J. Treatment resistant depression incidence estimates from studies of health insurance databases depend strongly on the details of the operating definition. Heliyon. 2018;4(7):e00707. doi:10.1016/j.heliyon.2018.e00707
   Web of Science ®Google Scholar
• Gaynes BN, Lux L, Gartlehner G, et al. Defining treatment-resistant depression. Depress Anxiety. 2020;37(2):134–145. doi:10.1002/da.22968
   PubMed Web of Science ®Google Scholar
• Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr Dis Treat. 2020;16:221–234. doi:10.2147/NDT.S198774
   PubMed Web of Science ®Google Scholar
• Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Moller HJ; World Federation of Societies of Biological Psychiatry, Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14(5):334–385. doi:10.3109/15622975.2013.804195
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Moon and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. Can J Psychiatry. 2016;61(9):540–560. doi:10.1177/0706743716659417
   PubMed Web of Science ®Google Scholar
• Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49(12):1087–1206. doi:10.1177/0004867415617657
   PubMed Web of Science ®Google Scholar
• Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29(5):459–525. doi:10.1177/0269881115581093
   PubMed Web of Science ®Google Scholar
• Thailand Ministry of Public Health. Clinical practice guideline of major depressive disorder for general practitioner: CPG-MDD-GP; 2010. Available from: http://www.thaidepression.com/www/news54/CPG-MDD-GP.pdf. Accessed March 16, 2020.
   Google Scholar
• Philippine Psychiatric Association. Consensus treatment guidelines on major depressive disorder in adults; 2017.
   Google Scholar
• Malaysia Ministry of Health. Clinical Practice Guidelines – management of major depressive disorder (second edition); 2019. Available from: http://www.moh.gov.my/moh/resources/Penerbitan/CPG/1)_CPG_Management_Major_Depressive_Disorder_(Second_Edition).pdf. Accessed March 16, 2020.
   Google Scholar
• Chongsuvivatwong V, Phua KH, Yap MT, et al. Health and health-care systems in Southeast Asia: diversity and transitions. Lancet. 2011;377(9793):429–437.
   Web of Science ®Google Scholar
• Nair R, Aggarwal R, Khanna D. Methods of formal consensus in classification/diagnostic criteria and guideline development. Semin Arthritis Rheum. 2011;41(2):95–105. doi:10.1016/j.semarthrit.2010.12.001
   PubMed Web of Science ®Google Scholar
• Brown S, Rittenbach K, Cheung S, McKean G, MacMaster FP, Clement F. Current and common definitions of treatment-resistant depression: findings from a systematic review and qualitative interviews. Can J Psychiatry. 2019;64(6):380–387. doi:10.1177/0706743719828965
   PubMed Web of Science ®Google Scholar
• Kraus C, Kadriu B, Lanzenberger R, Zarate CA Jr, Kasper S. Prognosis and improved outcomes in major depression: a review. Transl Psychiatry. 2019;9(1):127. doi:10.1038/s41398-019-0460-3
   PubMed Web of Science ®Google Scholar
• Philip MS, Carpenter LL, Tyrka AR, Price LH. Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. Expert Opin Pharmacother. 2010;11(5):709–722. doi:10.1517/14656561003614781
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354:1231–1242. doi:10.1056/NEJMoa052963
   PubMed Web of Science ®Google Scholar
• Schosser A, Serretti A, Souery D, et al. European Group for the Study of Resistant Depression (GSRD)--where have we gone so far: review of clinical and genetic findings. Eur Neuropsychopharmacol. 2012;22:453–468. doi:10.1016/j.euroneuro.2012.02.006
   PubMed Web of Science ®Google Scholar
• Bschor T, Baethge C. No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. Acta Psychiatr Scand. 2010;121:174–179. doi:10.1111/j.1600-0447.2009.01458.x
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry. 2008;63(7):699–704. doi:10.1016/j.biopsych.2007.08.010
   PubMed Web of Science ®Google Scholar
• Malhi GS, Hitching R, Berk M, Boyce P, Porter R, Fritz K. Pharmacological management of unipolar depression. Acta Psychiatr Scand Suppl. 2013;443:6–23. doi:10.1111/acps.12122
   PubMedGoogle Scholar
• Tundo A, de Filippis R, Proietti L. Pharmacologic approaches to treatment resistant depression: evidences and personal experience. World J Psychiatry. 2015;5(3):330–341. doi:10.5498/wjp.v5.i3.330
   Google Scholar
• Kellner CH, Greenberg RM, Murrough JW, Bryson EO, Briggs MC, Pasculli RM. ECT in treatment-resistant depression. Am J Psychiatry. 2012;169(12):1238–1244. doi:10.1176/appi.ajp.2012.12050648
   PubMed Web of Science ®Google Scholar
• Somani A, Kar SK. Efficacy of repetitive transcranial magnetic stimulation in treatment-resistant depression: the evidence thus far. Gen Psychiatr. 2019;32(4):e100074. doi:10.1136/gpsych-2019-100074
   Web of Science ®Google Scholar
• Gaynes BN, Lloyd SW, Lux L, et al. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. J Clin Psychiatry. 2014;75(5):477–89;quiz 489. doi:10.4088/JCP.13r08815
   PubMed Web of Science ®Google Scholar
• Wei Y, Zhu J, Pan S, Su H, Li H, Wang J. Meta-analysis of the efficacy and safety of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression. Shanghai Arch Psychiatry. 2017;29(6):328–342. doi:10.11919/j.issn.1002-0829.217106
   Google Scholar
• Health Quality Ontario. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis of randomized controlled trials. Ont Health Technol Assess Ser. 2016;16(5):1–66.
   Google Scholar
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746–758.
   PubMed Web of Science ®Google Scholar
• Janicak PG, O’Reardon JP, Sampson SM, et al. Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure and during reintroduction treatment. J Clin Psychiatry. 2008;69(2):222–232. doi:10.1016/S0140-6736(09)60046-5
   PubMed Web of Science ®Google Scholar
• Hansen PE, Ravnkilde B, Videbech P, et al. Low-frequency repetitive transcranial magnetic stimulation inferior to electroconvulsive therapy in treating depression. J ECT. 2011;27(1):26–32. doi:10.1097/YCT.0b013e3181d77645
   PubMed Web of Science ®Google Scholar
• Berlim MT, Van den Eynde F, Daskalakis ZJ. Efficacy and acceptability of high frequency repetitive transcranial magnetic stimulation (rTMS) versus electroconvulsive therapy (ECT) for major depression: a systematic review and meta-analysis of randomized trials. Depress Anxiety. 2013;30(7):614–623. doi:10.1002/da.22060
   Web of Science ®Google Scholar
• Ren J, Li H, Palaniyappan L, et al. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2014;51:181–189. doi:10.1016/j.pnpbp.2014.02.004
   PubMed Web of Science ®Google Scholar
• Song GM, Tian X, Shuai T, et al. Treatment of adults with treatment-resistant depression: electroconvulsive therapy plus antidepressant or electroconvulsive therapy alone? Evidence from an indirect comparison meta-analysis. Medicine. 2015;94(26):e1052. doi:10.1097/MD.0000000000001052
   Web of Science ®Google Scholar
• Milev RV, Giacobbe P, Kennedy SH, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 4. Neurostimulation treatments. Can J Psychiatry. 2016;61(9):561–575. doi:10.1177/0706743716660033
   PubMed Web of Science ®Google Scholar
• Abdelnaim MA, Langguth B, Deppe M, et al. Anti-suicidal efficacy of repetitive transcranial magnetic stimulation in depressive patients: a retrospective analysis of a large sample. Front Psychiatry. 2020;10:929. doi:10.3389/fpsyt.2019.00929
   Web of Science ®Google Scholar
• Desmyter S, Duprat R, Baeken C, Van Autreve S, Audenaert K, van Heeringen K. Accelerated intermittent theta burst stimulation for suicide risk in therapy-resistant depressed patients: a randomized, sham-controlled trials. Front Hum Neurosci. 2016;10:480. doi:10.3389/fnhum.2016.00480
   PubMed Web of Science ®Google Scholar
• Weissman MM, Markowitz JC. The future of psychotherapies for mood disorders. World Psychiatry. 2003;2(1):9–13.
   Google Scholar
• Ijaz S, Davies P, Williams CJ, Kessler D, Lewis G, Wiles N. Psychological therapies for treatment-resistant depression in adults. Cochrane Database Syst Rev. 2018;5:CD010558. doi:10.1002/14651858.CD010558.pub2
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic; 2019. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified. Accessed February 17, 2020.
   Google Scholar
• European Medicines Agency. Spravato; 2019. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/spravato. Accessed February 17, 2020.
   Google Scholar
• Bozymski KM, Crouse EL, Titus-Lay EN, Ott CA, Nofziger JL, Kirkwood CK. Esketamine: a novel option for treatment-resistant depression. Ann Pharmacother. 2020;54(6):567–576. doi:10.1177/1060028019892644
   PubMed Web of Science ®Google Scholar
• Bahr R, Lopez A, Rey JA. Intranasal Esketamine (SpravatoTM) for use in treatment-resistant depression in conjunction with an oral antidepressant. Pharm Ther. 2019;44(6):340–375.
   Google Scholar
• Kryst J, Kawalec P, Pilc A. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder. Expert Opin Pharmacother. 2020;21(1):9–20. doi:10.1080/14656566.2019.1683161
   PubMed Web of Science ®Google Scholar
• Ministry of Food and Drug Safety, South Korea. Integrated pharmaceutical information system. Spravato nasal spray (esketamine hydrochloride); 2020. Available from https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=202004585. Accessed July 14, 2020.
   Google Scholar
• Health Sciences Authority, Singapore. Healthcare professional guide for SPRAVATO® (esketamine) nasal spray; 2021. Available from: https://www.hsa.gov.sg/docs/default-source/hprg-vcb/pem-pmg-pac/spravato-pem_version2_08122021.pdf. Accessed November 10, 2022.
   Google Scholar
• Ministry of Health, Malaysia. Horizon scanning report, intranasal esketamine; 2019. Available from: https://www.moh.gov.my/index.php/database_stores/attach_download/561/41. Accessed November 10, 2022.
   Google Scholar
• Food and Drug Administration, Philippines. Esketamine; 2021 Available from: https://verification.fda.gov.ph/drug_productslist.php?cmd=search&t=drug_products&psearch=spravato&psearchtype=. Accessed November 10, 2022.
   Google Scholar
• Indonesian Food and Drug Supervisory Agency. Esketamine; 2021. Available from: https://cekbpom.pom.go.id//home/produk/n1rjqvhpj0f51249qe2151ctm4/all/row/10/page/1/order/4/DESC/search/5/esketamine. Accessed November 10, 2022.
   Google Scholar
• Fitch K, Bernstein SJ, Aguilar MD, et al. The RAND/UCLA appropriateness methos user’s manual; 2001. Available from: https://www.rand.org/pubs/monograph_reports/MR1269.html. Accessed July 14, 2020.
   Google Scholar